Prognostic value of steroid receptors after long-term follow-up of 2257 operable breast cancers
The prognostic value of oestrogen receptor (ER) and progesterone receptor (PR) was estimated through a multicentric study of 2257 operable breast cancer patients followed up for a median of 8.5 years. None of the patients had received adjuvant therapy. The series included 33.3% stage I patients, 57....
Saved in:
Published in | British journal of cancer Vol. 73; no. 12; pp. 1545 - 1551 |
---|---|
Main Authors | , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Basingstoke
Nature Publishing Group
01.06.1996
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | The prognostic value of oestrogen receptor (ER) and progesterone receptor (PR) was estimated through a multicentric study of 2257 operable breast cancer patients followed up for a median of 8.5 years. None of the patients had received adjuvant therapy. The series included 33.3% stage I patients, 57.1% stage II, 5.7% stage IIIa and 2.4% stage IIIb. At the end point of the study 589 metastases and 537 deaths from cancer were recorded. Receptor measurements were performed by radiolgand assay according to a uniform protocol. A total of 68.8% of the tumous were ER positive and 54.0% PR positive ( > or = 10 fmol mg-1 cytosol protein). In univariate analysis, ER and PR status (positive/negative) were of prognostic value (P < 0.001) for the disease-free interval (DFI), the metastases-free interval (MFI) and the overall survival (OS). The OS of the patients after a first metastasis was also significantly different between ER-positive and -negative tumours (P < 0.001). In multivariate analysis (Cox proportional hazard model, 1665 patients), only the ER status showed a significant difference (P < 0.01) between positive and negative groups regarding the DFI, MFI and OS. By using Cox non-proportional, time-dependent models, we show that the predictive value of ER status of the primary tumour decreases by approximately 20% per year, losing its significance after 8 years of follow-up. Overall, when compared with TNM and histological grading, ER and PR status have a low prognostic value, their major interest remaining solely in the domain of therapeutic decision. |
---|---|
AbstractList | The prognostic value of oestrogen receptor (ER) and progesterone receptor (PR) was estimated through a multicentric study of 2257 operable breast cancer patients followed up for a median of 8.5 years. None of the patients had received adjuvant therapy. The series included 33.3% stage I patients, 57.1% stage II, 5.7% stage IIIa and 2.4% stage IIIb. At the end point of the study 589 metastases and 537 deaths from cancer were recorded. Receptor measurements were performed by radiolgand assay according to a uniform protocol. A total of 68.8% of the tumous were ER positive and 54.0% PR positive ( > or = 10 fmol mg-1 cytosol protein). In univariate analysis, ER and PR status (positive/negative) were of prognostic value (P < 0.001) for the disease-free interval (DFI), the metastases-free interval (MFI) and the overall survival (OS). The OS of the patients after a first metastasis was also significantly different between ER-positive and -negative tumours (P < 0.001). In multivariate analysis (Cox proportional hazard model, 1665 patients), only the ER status showed a significant difference (P < 0.01) between positive and negative groups regarding the DFI, MFI and OS. By using Cox non-proportional, time-dependent models, we show that the predictive value of ER status of the primary tumour decreases by approximately 20% per year, losing its significance after 8 years of follow-up. Overall, when compared with TNM and histological grading, ER and PR status have a low prognostic value, their major interest remaining solely in the domain of therapeutic decision. The prognostic value of oestrogen receptor (ER) and progesterone receptor (PR) was estimated through a multicentric study of 2257 operable breast cancer patients followed up for a median of 8.5 years. None of the patients had received adjuvant therapy. The series included 33.3% stage I patients, 57.1% stage II, 5.7% stage IIIa and 2.4% stage IIIb. At the end point of the study 589 metastases and 537 deaths from cancer were recorded. Receptor measurements were performed by radiolgand assay according to a uniform protocol. A total of 68.8% of the tumous were ER positive and 54.0% PR positive ( > or = 10 fmol mg-1 cytosol protein). In univariate analysis, ER and PR status (positive/negative) were of prognostic value (P < 0.001) for the disease-free interval (DFI), the metastases-free interval (MFI) and the overall survival (OS). The OS of the patients after a first metastasis was also significantly different between ER-positive and -negative tumours (P < 0.001). In multivariate analysis (Cox proportional hazard model, 1665 patients), only the ER status showed a significant difference (P < 0.01) between positive and negative groups regarding the DFI, MFI and OS. By using Cox non-proportional, time-dependent models, we show that the predictive value of ER status of the primary tumour decreases by approximately 20% per year, losing its significance after 8 years of follow-up. Overall, when compared with TNM and histological grading, ER and PR status have a low prognostic value, their major interest remaining solely in the domain of therapeutic decision. |
Author | BROET, P MAGDELENAT, H MILLON, R DELARUE, J. C SPYRATOS, F PICHON, M. F BASUYAU, J. P SAEZ, S RALLET, A COURRIERE, P ASSELAIN, B |
AuthorAffiliation | Groupe de Biopathologie Tissulaire et Moléculaire, Fédération des Centres de Lutte contre le Cancer, Paris, France |
AuthorAffiliation_xml | – name: Groupe de Biopathologie Tissulaire et Moléculaire, Fédération des Centres de Lutte contre le Cancer, Paris, France |
Author_xml | – sequence: 1 givenname: M. F surname: PICHON fullname: PICHON, M. F organization: Groupe de Biopathologie Tissulaire et Moléculaire, Fédération des Centres de Lutte contre le Cancer, 101 rue de Tolbiac, 75654 Paris, France – sequence: 2 givenname: P surname: BROET fullname: BROET, P organization: Groupe de Biopathologie Tissulaire et Moléculaire, Fédération des Centres de Lutte contre le Cancer, 101 rue de Tolbiac, 75654 Paris, France – sequence: 3 givenname: B surname: ASSELAIN fullname: ASSELAIN, B organization: Groupe de Biopathologie Tissulaire et Moléculaire, Fédération des Centres de Lutte contre le Cancer, 101 rue de Tolbiac, 75654 Paris, France – sequence: 4 givenname: H surname: MAGDELENAT fullname: MAGDELENAT, H organization: Groupe de Biopathologie Tissulaire et Moléculaire, Fédération des Centres de Lutte contre le Cancer, 101 rue de Tolbiac, 75654 Paris, France – sequence: 5 givenname: J. C surname: DELARUE fullname: DELARUE, J. C organization: Groupe de Biopathologie Tissulaire et Moléculaire, Fédération des Centres de Lutte contre le Cancer, 101 rue de Tolbiac, 75654 Paris, France – sequence: 6 givenname: F surname: SPYRATOS fullname: SPYRATOS, F organization: Groupe de Biopathologie Tissulaire et Moléculaire, Fédération des Centres de Lutte contre le Cancer, 101 rue de Tolbiac, 75654 Paris, France – sequence: 7 givenname: J. P surname: BASUYAU fullname: BASUYAU, J. P organization: Groupe de Biopathologie Tissulaire et Moléculaire, Fédération des Centres de Lutte contre le Cancer, 101 rue de Tolbiac, 75654 Paris, France – sequence: 8 givenname: S surname: SAEZ fullname: SAEZ, S organization: Groupe de Biopathologie Tissulaire et Moléculaire, Fédération des Centres de Lutte contre le Cancer, 101 rue de Tolbiac, 75654 Paris, France – sequence: 9 givenname: A surname: RALLET fullname: RALLET, A organization: Groupe de Biopathologie Tissulaire et Moléculaire, Fédération des Centres de Lutte contre le Cancer, 101 rue de Tolbiac, 75654 Paris, France – sequence: 10 givenname: P surname: COURRIERE fullname: COURRIERE, P organization: Groupe de Biopathologie Tissulaire et Moléculaire, Fédération des Centres de Lutte contre le Cancer, 101 rue de Tolbiac, 75654 Paris, France – sequence: 11 givenname: R surname: MILLON fullname: MILLON, R organization: Groupe de Biopathologie Tissulaire et Moléculaire, Fédération des Centres de Lutte contre le Cancer, 101 rue de Tolbiac, 75654 Paris, France |
BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=3119524$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/8664127$$D View this record in MEDLINE/PubMed |
BookMark | eNpVkc1rFDEYxkOp1G3tzauQg3jqrPmYZJKLUIrWQkEPeg6ZzJt1SjYZk5kW_3sz7LLoKR_Pj-fJm-cSnccUAaG3lGwp4epj_-S2VGu5ZZqeoQ0VnDVUse4cbQghXUM0I6_RZSlP9aiJ6i7QhZKypazbIPM9p11MZR4dfrZhAZw8LjPkNA44g4NpTrlg6-sVDinumrrZY59CSC_NMq04Y6LDaYJs-wC4z2DLjJ2NDnJ5g155GwpcH9cr9PPL5x93X5vHb_cPd7ePjWu1nhthqaNkUIMArnhLpZJaArFeaGGJ7xwF6XvZE8e55K0iqndDHZrazgrtBb9Cnw6-09LvYXAQ52yDmfK4t_mPSXY0_ytx_GV26dkw0rWipdXgw9Egp98LlNnsx-IgBBshLcV0itK2TlrBmwPociolgz-FUGLWQkwtxKyFmFpIxd_9-7ATfGyg6u-Pui3OBp_rv43lhHFKtWBtxfABi3ZeMpz0mrVGrUl_AR1ToS8 |
CODEN | BJCAAI |
CitedBy_id | crossref_primary_10_1016_j_hoc_2007_03_009 crossref_primary_10_1186_bcr1639 crossref_primary_10_1002__SICI_1097_0320_19990415_38_2_61__AID_CYTO3_3_0_CO_2_X crossref_primary_10_1002_jso_22120 crossref_primary_10_5858_2002_126_0325_MSOERN crossref_primary_10_1097_PPO_0b013e3181ce4ae1 crossref_primary_10_1097_00000658_200201000_00003 crossref_primary_10_2217_14796694_4_1_15 crossref_primary_10_1046_j_1440_1827_2003_01441_x crossref_primary_10_1111_j_0006_341X_2001_00844_x crossref_primary_10_1186_1471_2105_9_63 crossref_primary_10_1002_1097_0215_20000915_87_6_860__AID_IJC16_3_0_CO_2_Y crossref_primary_10_1016_S0959_8049_02_00067_9 crossref_primary_10_1016_S1607_551X_08_70146_3 crossref_primary_10_1007_s10549_011_1564_5 crossref_primary_10_1038_sj_bjc_6690389 crossref_primary_10_1038_sj_onc_1210269 crossref_primary_10_1016_j_critrevonc_2007_11_004 crossref_primary_10_1177_172460080301800102 crossref_primary_10_1016_S1741_8372_04_02459_4 crossref_primary_10_1038_modpathol_3800229 crossref_primary_10_1148_radiol_2462070169 crossref_primary_10_1186_bcr1631 crossref_primary_10_1089_jwh_1996_5_505 crossref_primary_10_1177_172460080201700103 crossref_primary_10_5812_ircmj_23038v2 crossref_primary_10_1038_modpathol_3800255 crossref_primary_10_1080_07357900801891628 crossref_primary_10_1158_1078_0432_CCR_08_1763 crossref_primary_10_1054_brst_2000_0171 crossref_primary_10_1007_s10549_010_0998_5 crossref_primary_10_1038_sj_bjc_6600335 crossref_primary_10_1080_02841860310004724 crossref_primary_10_1023_A_1006011328655 crossref_primary_10_1186_s13000_023_01433_6 crossref_primary_10_1016_S0889_8588_05_70058_7 crossref_primary_10_1158_0008_5472_CAN_07_2822 crossref_primary_10_1074_jbc_M109_078212 crossref_primary_10_1158_0008_5472_CAN_04_3953 crossref_primary_10_1186_bcr2158 crossref_primary_10_1080_01443610600984669 crossref_primary_10_1002_cncr_11294 crossref_primary_10_1016_j_jcpa_2014_04_001 crossref_primary_10_1177_172460080101600108 crossref_primary_10_1200_JCO_2009_26_4200 crossref_primary_10_1016_j_prp_2009_12_003 crossref_primary_10_1210_er_2010_0016 crossref_primary_10_2217_17520363_2_2_181 crossref_primary_10_1016_j_breast_2014_01_007 crossref_primary_10_1016_S0925_4439_00_00014_4 crossref_primary_10_1111_vco_12795 crossref_primary_10_1007_s10549_008_0110_6 crossref_primary_10_1002_cncr_22381 crossref_primary_10_1023_A_1006141703224 crossref_primary_10_1159_000336539 crossref_primary_10_1200_JCO_2007_12_2747 crossref_primary_10_1001_jamanetworkopen_2021_14904 crossref_primary_10_1016_S1068_607X_00_00021_4 crossref_primary_10_1186_s12957_015_0582_x crossref_primary_10_3390_ijms21020511 crossref_primary_10_1038_sj_bjc_6690249 crossref_primary_10_1016_j_steroids_2012_02_013 crossref_primary_10_1016_j_jmva_2004_02_009 crossref_primary_10_1002_1097_0142_20010715_92_2_249__AID_CNCR1316_3_0_CO_2_P crossref_primary_10_3389_fonc_2020_00617 crossref_primary_10_1002_jso_10264 crossref_primary_10_1111_j_1445_1433_2004_03215_x crossref_primary_10_2460_javma_235_4_391 crossref_primary_10_4103_jomt_jomt_23_20 crossref_primary_10_1023_A_1006046107249 crossref_primary_10_1002_cncr_21262 crossref_primary_10_1016_S0959_8049_96_00531_X crossref_primary_10_1136_jcp_2005_035550 crossref_primary_10_1007_s10549_010_1153_z crossref_primary_10_1097_00129039_200609000_00017 crossref_primary_10_1097_COC_0b013e3181967d72 crossref_primary_10_1080_10408360600739218 crossref_primary_10_1002_ijc_10171 crossref_primary_10_1111_j_1439_0531_2011_01816_x crossref_primary_10_1093_jnci_91_8_728 crossref_primary_10_1007_s10549_010_0746_x crossref_primary_10_1038_sj_bjc_6690279 crossref_primary_10_1158_1078_0432_CCR_0102_03 crossref_primary_10_1007_s10549_019_05400_y crossref_primary_10_1002__SICI_1097_0142_19991115_86_10_2083__AID_CNCR28_3_0_CO_2_2 crossref_primary_10_1016_S0025_7753_01_72251_8 crossref_primary_10_1177_8756479318792043 crossref_primary_10_1007_s10549_005_9065_z crossref_primary_10_1001_jamanetworkopen_2019_18160 crossref_primary_10_1007_s00428_005_0003_6 |
ContentType | Journal Article |
Copyright | 1996 INIST-CNRS |
Copyright_xml | – notice: 1996 INIST-CNRS |
DBID | IQODW CGR CUY CVF ECM EIF NPM AAYXX CITATION 7X8 5PM |
DOI | 10.1038/bjc.1996.291 |
DatabaseName | Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef MEDLINE - Academic PubMed Central (Full Participant titles) |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef MEDLINE - Academic |
DatabaseTitleList | MEDLINE MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1532-1827 |
EndPage | 1551 |
ExternalDocumentID | 10_1038_bjc_1996_291 8664127 3119524 bjc1996291 |
Genre | Research Support, Non-U.S. Gov't Multicenter Study Journal Article |
GroupedDBID | - -Q- 02 08R 0R 23N 39C 3V. 4.4 53G 55 5GY 5RE 70F 7RV 7X7 88E 8AO 8C1 8FI 8FJ 8R4 8R5 8WZ A6W AADWK AAPBV AAWBL AAWTL AAYJO AAZLF ABAWZ ABDBF ABDEU ABFLS ABGIJ ABOCM ABPTK ABUWG ACGFS ACKTT ACPRK ADACO ADBBV ADBIT ADHDB ADQMX AEDAW AEJRE AENEX AEXYK AFKRA AFRAH AFSHS AGEZK AHMBA AHSBF AJRNO ALFFA ALMA_UNASSIGNED_HOLDINGS AN0 ASPBG AVWKF AXYYD AZFZN B0M BAWUL BBAFP BBNVY BENPR BHPHI BKEYQ BKKNO BNQBC BPHCQ BVXVI CAG COF CS3 DIK DU5 E3Z EAD EAP EAS EBC EBD EBLON EBS EE. EIOEI EJD EMB EMK EPL ESX EX3 F5P FDQFY FEDTE FERAY FIZPM FRJ FSGXE FYUFA GJ GX1 HCIFZ HVGLF HYE HZ IH2 J5H JSO KQ8 M1P M41 M7P NAO NAPCQ O9- OK1 P2P PQEST PQQKQ PQUKI PRINS PROAC PSQYO Q- Q2X RIG RNT RNTTT RPM SNX SNYQT SV3 SWTZT TAOOD TBHMF TDRGL TR2 TUS UDS VH1 W2D WH7 WOW X7M XFK Y6R ZA5 ZGI --- .55 .GJ 0R~ 36B 406 6J9 AANZL AATNV AAUGY AAYFA ABLJU ACBMV ACBRV ACBYP ACGFO ACIGE ACRQY ACTTH ACVWB ADFRT ADMDM ADYYL AEFTE AEVLU AFNRJ AGAYW AGGBP AGHAI AI. AILAN AJCLW AJDOV AMRJV AMYLF AOIJS CCPQU DNIVK DPUIP EMOBN HZ~ IQODW IWAJR JZLTJ NQJWS NYICJ SOHCF SRMVM UKHRP ~02 ~8M AACDK AASML AAYZH ABAKF ABZZP ACAOD ACZOJ AEFQL AEMSY AFBBN AGQEE AIGIU CGR CUY CVF ECM EIF FIGPU HMCUK NPM AAYXX CITATION 7X8 5PM |
ID | FETCH-LOGICAL-c499t-5a1c10d8d5e3834168696e0af595a0f7c1e6fb6b0c33634808bcd1991a7a59f53 |
IEDL.DBID | RPM |
ISSN | 0007-0920 |
IngestDate | Tue Sep 17 21:24:23 EDT 2024 Fri Aug 16 23:48:54 EDT 2024 Fri Aug 23 02:26:45 EDT 2024 Wed Oct 16 00:47:37 EDT 2024 Sun Oct 29 17:08:25 EDT 2023 Thu Oct 07 19:36:09 EDT 2021 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 12 |
Keywords | Human Mammary gland diseases Prognosis Follow up study Estrogen Mammary gland Progesterone Malignant tumor Sex steroid hormone Ovarian hormone Hormonal receptor |
Language | English |
License | CC BY 4.0 This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c499t-5a1c10d8d5e3834168696e0af595a0f7c1e6fb6b0c33634808bcd1991a7a59f53 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
OpenAccessLink | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2074541/ |
PMID | 8664127 |
PQID | 78114225 |
PQPubID | 23479 |
PageCount | 7 |
ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_2074541 proquest_miscellaneous_78114225 crossref_primary_10_1038_bjc_1996_291 pubmed_primary_8664127 pascalfrancis_primary_3119524 nature_primary_bjc1996291 |
ProviderPackageCode | ABDEU AEDAW AAZLF -Q- AADWK AAYJO 70F ADQMX EE. RNTTT SWTZT ABGIJ RNT NAO |
PublicationCentury | 1900 |
PublicationDate | 1996-06-01 |
PublicationDateYYYYMMDD | 1996-06-01 |
PublicationDate_xml | – month: 06 year: 1996 text: 1996-06-01 day: 01 |
PublicationDecade | 1990 |
PublicationPlace | Basingstoke |
PublicationPlace_xml | – name: Basingstoke – name: England |
PublicationTitle | British journal of cancer |
PublicationTitleAlternate | Br J Cancer |
PublicationYear | 1996 |
Publisher | Nature Publishing Group |
Publisher_xml | – name: Nature Publishing Group |
References | 9192994 - Br J Cancer. 1997;75(12):1854 |
References_xml | |
SSID | ssj0009087 |
Score | 1.9081442 |
Snippet | The prognostic value of oestrogen receptor (ER) and progesterone receptor (PR) was estimated through a multicentric study of 2257 operable breast cancer... |
SourceID | pubmedcentral proquest crossref pubmed pascalfrancis nature |
SourceType | Open Access Repository Aggregation Database Index Database Publisher |
StartPage | 1545 |
SubjectTerms | Adult Aged Aged, 80 and over Analysis of Variance Biological and medical sciences Breast Neoplasms - pathology Breast Neoplasms - surgery Breast Neoplasms - ultrastructure Female Follow-Up Studies Gynecology. Andrology. Obstetrics Humans Mammary gland diseases Medical sciences Middle Aged Neoplasm Metastasis Prognosis Radioligand Assay Receptors, Estrogen - analysis Receptors, Progesterone - analysis Risk Factors Time Factors Tumors |
Title | Prognostic value of steroid receptors after long-term follow-up of 2257 operable breast cancers |
URI | http://dx.doi.org/10.1038/bjc.1996.291 https://www.ncbi.nlm.nih.gov/pubmed/8664127 https://search.proquest.com/docview/78114225 https://pubmed.ncbi.nlm.nih.gov/PMC2074541 |
Volume | 73 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1La9wwEB6SQEuglPQR6rZJdWiP3rWth-VjCQ1Jy5YcGsjNSLLUbkhssw_69zvjF9mSU84zBjMz0oykb74B-OxTx20uZCwtboHCGhljGpExZmYsFnzlsoy6kRc_1cW1-H4jb_ZAjr0wHWjf2eWsvruf1cs_HbayvXfzESc2v1qcZZj3pEjn-7Cfcz4e0Uem3UT3RJl0B1dkyYB2T7ie21tH3XlqlhXpITzTSolunMyDjDTxab5ozRqtFPrxFo_Vn__DKB_kpfMjeDkUlOxr_-OvYM_Xr-H5YngyfwPl1aohMB2KGTF7e9YERuwIzbJiuN35lubtsG5WOLtr6t8xbdYsYHw0f-NtS-q4GnPWtH5FfVbMEo59wxzFy2r9Fq7Pv_06u4iHqQqxw9PNJpYmdWlS6Up6PJ1iPaZVoXxigiykSULuUq-CVTZxnCsudKKtqwggZXIjiyD5MRzUTe3fAeOVzWjRq0ob4SzqJKaSIhgs8rhTIYIvo2XLtifPKLtHb65L9EVJvijRFxFEvdknLZSSsJOd7HhiUuFEVpeJCD6NnilxZdBzh6l9s12X1EMr0EARHPd-mj4dHB9BvuPASU6U27sSjMSOenuIvPdP_vIDHPa4b7rH-QgHm9XWn2BZs7GnWNBf_jjtgvkfA8T4Zw |
link.rule.ids | 230,315,733,786,790,891,27955,27956,53825,53827 |
linkProvider | National Library of Medicine |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwEB6VIqAS4l0RoNQHOCabxI8kR1RRLdCtemhRb5HtOLDQJtFuVkj8embyUrfiAuexD8k39oztb74BeOciy00ipC8NboHCaOljGJE-RmZMFlxh45iqkRenan4hPl_Kyx2QYy1MR9q3ZhlUV9dBtfzecSubazsbeWKzs8VRjHFPimh2B-7ieo3leEgftXbDtJfKpFu4LA4HvnvI05n5Yak-TwVxFu3BvVQp0TWUuRGTJkXNh41e438q-wYXf8tAbxMpb0Sm48fwdfymnpDyM9i0JrC_b8k9_vNHP4FHQ67KPvTmp7DjqmdwfzG8xj-H_GxVE08PzYxEwx2rS0bCC_WyYLiTuoZa-bCuDTm7qqtvPsUBVqLr1b_8TUPDcaEnrG7cikq4mCGKfMssueJq_QIujj-eH839oWGDb_Hg1PpSRzYKi7SQDg--mOqlKlMu1KXMpA7LxEZOlUaZ0HKuuEjD1NiCuFc60TIrJd-H3aqu3EtgvDAx7SeqSLWwBseEupCi1Jg_cqtKD96PkOVNr8uRd-_pPM0R5JxAzhFkD7wez2kUWsnY2Q62IJ6GcNLBi4UHhyPkOS46eknRlas365zKcwX-IA_2eweYpg4e5UGy5RmTndS8ty2Id6fqPeD76r9nHsKD-fniJD_5dPrlNez19HK6LnoDu-1q4w4we2rN226t_AGc9Rlq |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELagiKpSxbsiQKkPcMzTjyRHVFiVx1Z7oFLFJbIdGxbaJNrNqhK_npm8tFtx6nnGh-Qbe8b2528IeWdjw3TKhS80LIFcK-FDGhE-ZGYoFmxpkgRfI8_P5dkF_3IpLrdafXWkfaOXQXV1HVTLXx23srk24cgTCxfz0wTynuBx2JQuvE8ewJxN0nGjPurtRlkvl4kncXkSDZz3iGWh_m3wjZ4Mkjw-IA8zKXnXVGYrL02qmoeNWsO_cn2Ti_9VobfJlFvZafaY_Bi_qyel_Ak2rQ7M31uSj3f68Cfk0VCz0g-9y1Nyz1bPyP58uJV_TorFqka-HpgpiodbWjuKAgz1sqSwotoGW_rQrh05vaqrnz7mA-ogBOsbf9OgO0z4lNaNXeFTLqqRKt9SgyG5Wr8gF7NP30_P_KFxg29gA9X6QsUmjsqsFBY2wFDyZTKXNlJO5EJFLjWxlU5LHRnGJONZlGlTIgdLpUrkTrAjslfVlX1JKCt1guuKLDPFjQafSJWCOwV1JDPSeeT9CFvR9PocRXevzrICgC4Q6AKA9ojXYzp5gRWNne14B-bJhaEeXsI9cjLCXsDkwxsVVdl6sy7wmS6HH-SRoz4IpqFDVHkk3YmOyY6q3rsWwLxT9x4wfnXnkSdkf_FxVnz7fP71NTnoWeZ4avSG7LWrjT2GIqrVb7vp8g9nIBvq |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Prognostic+value+of+steroid+receptors+after+long-term+follow-up+of+2257+operable+breast+cancers&rft.jtitle=British+journal+of+cancer&rft.au=Pichon%2C+M+F&rft.au=Broet%2C+P&rft.au=Magdelenat%2C+H&rft.au=Delarue%2C+J+C&rft.date=1996-06-01&rft.issn=0007-0920&rft.volume=73&rft.issue=12&rft.spage=1545&rft.epage=1551&rft_id=info:doi/10.1038%2Fbjc.1996.291&rft.externalDBID=NO_FULL_TEXT |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0007-0920&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0007-0920&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0007-0920&client=summon |